Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference
April 13 2023 - 7:00AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced that Chen Schor, President
and Chief Executive Officer will participate in a panel at the
Canaccord Genuity Horizons in Oncology Virtual Conference being
held April 20, 2023.
Details of the event are as follows: Panel: “Off-the-Shelf CART
– Current Snapshot” Date: Thursday, April 20, 2023 Time: 11:00 a.m.
ET
The Adicet Bio team will be available for one-on-one meetings
throughout the conference. Please contact your sales representative
at Canaccord Genuity to register for a meeting with the
company.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230413005139/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2023 to Jul 2024